

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

- 1.-21. (Canceled)
22. (Currently Amended): A composition to treat hepatic fibrosis ~~in a human~~ in a subject comprising a therapeutically effective amount of unitary doses of viral particles of a recombinant adenoviral vector,
- wherein said unitary dose is from about 10^7 to about 10^{14} viral particles;
- wherein the adenoviral vector ~~comprises an adenoviral vector selected from the group consisting of~~ is the vector contained in ATCC Deposit No. PTA-10532;
- and a pharmaceutically compatible carrier.
23. (Canceled)
24. (Currently Amended): A method of treating hepatic fibrosis in a subject ~~fibrotic disorders in a human patient~~, comprising delivering the composition of claim 22 by an intravenous administrative route to the subject ~~a liver~~; and ~~expressing the therapeutic protein in the liver from the recombinant adenoviral vector of the composition to treat the hepatic fibrotic disorders.~~
- 25.-34. (Canceled)